Why the study?
Does oral tacrolimus reduce the incidence of biopsy-proven acute rejection compared to cyclosporine in heart transplant recipients?
Population
314 heart transplant recipients (157 per group) undergoing antibody induction in a European trial.
Comparison
Oral tacrolimus-based immunosuppression in… vs Oral cyclosporine microemulsion-based…
Design
RCT, 1:1, Blinded central evaluation of protocol biopsies
Follow-up
18 months
Authors
Loading...
Tacrolimus reduces acute rejection versus cyclosporine after heart transplant; confirms superiority of tacrolimus-based regimens in this RCT.
Does oral tacrolimus reduce the incidence of biopsy-proven acute rejection compared to cyclosporine in heart transplant recipients?
Tacrolimus-based immunosuppression provides superior prevention of acute rejection compared to cyclosporine in heart transplant recipients, though it is associated with a higher risk of new-onset diabetes.
Grimm et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: